CytomX Historical Income Statement

CTMX Stock

USD 1.02 0.06 6.25%

Historical analysis of CytomX Therapeutics income statement accounts such as Interest Expense of 2.1 M, Selling General Administrative of 28.8 M or Total Revenue of 54.2 M can show how well CytomX Therapeutics performed in making a profits. Evaluating CytomX Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of CytomX Therapeutics's future profits or losses.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining CytomX Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether CytomX Therapeutics is a good buy for the upcoming year.

Net Income Gross Profit

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CytomX Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

For more information on how to buy CytomX Stock please use our How to Invest in CytomX Therapeutics guide.

About CytomX Income Statement Analysis

CytomX Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to CytomX Therapeutics shareholders. The income statement also shows CytomX investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

CytomX Therapeutics Income Statement Chart

At this time, CytomX Therapeutics' Depreciation And Amortization is fairly stable compared to the past year. Other Operating Expenses is likely to rise to about 115.4 M in 2024, whereas Interest Expense is likely to drop slightly above 2.1 M in 2024.

Selling General Administrative Total Revenue Gross Profit Other Operating Expenses

Total Revenue

Total revenue comprises all receipts CytomX Therapeutics generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Gross Profit

Gross profit is a required income statement account that reflects total revenue of CytomX Therapeutics minus its cost of goods sold. It is profit before CytomX Therapeutics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of CytomX Therapeutics. It is also known as CytomX Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Most accounts from CytomX Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into CytomX Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CytomX Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

For more information on how to buy CytomX Stock please use our How to Invest in CytomX Therapeutics guide.At this time, CytomX Therapeutics' Depreciation And Amortization is fairly stable compared to the past year. Other Operating Expenses is likely to rise to about 115.4 M in 2024, whereas Interest Expense is likely to drop slightly above 2.1 M in 2024.

	2021	2022	2023	2024 (projected)
Gross Profit	69.6M	53.2M	101.2M	54.2M
Total Revenue	69.6M	53.2M	101.2M	54.2M

Gross Profit Total Revenue

CytomX Therapeutics income statement Correlations

	Depreciation And Amortization	Interest Expense	Selling General Administrative	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Research Development	Ebitda	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Net Income From Continuing Ops	Tax Provision	Interest Income	Net Interest Income	Non Operating Income Net Other	Reconciled Depreciation	Extraordinary Items	Selling And Marketing Expenses
Depreciation And Amortization		0.31	0.78	0.81	0.81	0.79	-0.43	-0.61	0.78	-0.58	-0.24	0.79	-0.39	0.34	-0.31	-0.51	-0.24	-0.5	0.3	0.27	-0.05	0.78	-0.13	-0.13
Interest Expense	0.31		0.4	0.25	0.25	0.46	-0.49	-0.48	0.48	-0.48	-0.2	0.46	-0.44	0.59	-0.43	-0.1	-0.4	-0.12	0.59	0.58	0.49	0.49	-0.08	-0.08
Selling General Administrative	0.78	0.4		0.85	0.85	0.99	-0.71	-0.75	0.98	-0.74	-0.22	0.99	-0.65	0.44	-0.64	-0.07	-0.61	0.0	0.55	0.51	0.05	0.84	-0.19	-0.19
Total Revenue	0.81	0.25	0.85		1.0	0.85	-0.34	-0.45	0.85	-0.43	-0.16	0.85	-0.27	0.53	-0.25	-0.14	-0.19	-0.13	0.59	0.58	-0.06	0.74	-0.31	-0.31
Gross Profit	0.81	0.25	0.85	1.0		0.85	-0.34	-0.45	0.85	-0.43	-0.16	0.85	-0.27	0.53	-0.25	-0.14	-0.19	-0.13	0.59	0.58	-0.06	0.74	-0.31	-0.31
Other Operating Expenses	0.79	0.46	0.99	0.85	0.85		-0.74	-0.78	1.0	-0.77	-0.17	1.0	-0.67	0.45	-0.66	-0.07	-0.61	-0.01	0.58	0.55	0.16	0.83	-0.16	-0.16
Operating Income	-0.43	-0.49	-0.71	-0.34	-0.34	-0.74		0.97	-0.74	0.97	0.04	-0.74	0.99	0.04	0.99	0.05	0.96	-0.06	-0.31	-0.26	-0.44	-0.48	-0.41	-0.41
Ebit	-0.61	-0.48	-0.75	-0.45	-0.45	-0.78	0.97		-0.78	1.0	0.08	-0.78	0.96	0.04	0.93	0.22	0.89	0.12	-0.28	-0.23	-0.4	-0.55	-0.42	-0.42
Research Development	0.78	0.48	0.98	0.85	0.85	1.0	-0.74	-0.78		-0.77	-0.15	1.0	-0.67	0.44	-0.67	-0.07	-0.61	-0.02	0.59	0.56	0.19	0.82	-0.15	-0.15
Ebitda	-0.58	-0.48	-0.74	-0.43	-0.43	-0.77	0.97	1.0	-0.77		0.08	-0.77	0.97	0.05	0.94	0.21	0.9	0.1	-0.27	-0.23	-0.41	-0.54	-0.43	-0.43
Cost Of Revenue	-0.24	-0.2	-0.22	-0.16	-0.16	-0.17	0.04	0.08	-0.15	0.08		-0.17	0.0	-0.4	0.01	-0.09	0.1	-0.11	-0.23	-0.3	-0.02	-0.54	0.26	0.26
Total Operating Expenses	0.79	0.46	0.99	0.85	0.85	1.0	-0.74	-0.78	1.0	-0.77	-0.17		-0.67	0.45	-0.66	-0.07	-0.61	-0.01	0.58	0.55	0.16	0.83	-0.16	-0.16
Income Before Tax	-0.39	-0.44	-0.65	-0.27	-0.27	-0.67	0.99	0.96	-0.67	0.97	0.0	-0.67		0.14	0.99	0.11	0.96	-0.02	-0.2	-0.15	-0.41	-0.42	-0.49	-0.49
Total Other Income Expense Net	0.34	0.59	0.44	0.53	0.53	0.45	0.04	0.04	0.44	0.05	-0.4	0.45	0.14		0.12	0.13	0.11	0.06	0.69	0.71	-0.05	0.64	-0.78	-0.78
Net Income	-0.31	-0.43	-0.64	-0.25	-0.25	-0.66	0.99	0.93	-0.67	0.94	0.01	-0.66	0.99	0.12		-0.06	0.98	-0.18	-0.28	-0.23	-0.48	-0.38	-0.45	-0.45
Income Tax Expense	-0.51	-0.1	-0.07	-0.14	-0.14	-0.07	0.05	0.22	-0.07	0.21	-0.09	-0.07	0.11	0.13	-0.06		-0.07	0.98	0.49	0.5	0.38	-0.27	-0.26	-0.26
Net Income From Continuing Ops	-0.24	-0.4	-0.61	-0.19	-0.19	-0.61	0.96	0.89	-0.61	0.9	0.1	-0.61	0.96	0.11	0.98	-0.07		-0.2	-0.23	-0.19	-0.41	-0.38	-0.44	-0.44
Tax Provision	-0.5	-0.12	0.0	-0.13	-0.13	-0.01	-0.06	0.12	-0.02	0.1	-0.11	-0.01	-0.02	0.06	-0.18	0.98	-0.2		0.44	0.45	0.36	-0.22	-0.18	-0.18
Interest Income	0.3	0.59	0.55	0.59	0.59	0.58	-0.31	-0.28	0.59	-0.27	-0.23	0.58	-0.2	0.69	-0.28	0.49	-0.23	0.44		0.99	0.52	0.4	-0.35	-0.35
Net Interest Income	0.27	0.58	0.51	0.58	0.58	0.55	-0.26	-0.23	0.56	-0.23	-0.3	0.55	-0.15	0.71	-0.23	0.5	-0.19	0.45	0.99		0.52	0.41	-0.37	-0.37
Non Operating Income Net Other	-0.05	0.49	0.05	-0.06	-0.06	0.16	-0.44	-0.4	0.19	-0.41	-0.02	0.16	-0.41	-0.05	-0.48	0.38	-0.41	0.36	0.52	0.52		-0.12	0.37	0.37
Reconciled Depreciation	0.78	0.49	0.84	0.74	0.74	0.83	-0.48	-0.55	0.82	-0.54	-0.54	0.83	-0.42	0.64	-0.38	-0.27	-0.38	-0.22	0.4	0.41	-0.12		-0.38	-0.38
Extraordinary Items	-0.13	-0.08	-0.19	-0.31	-0.31	-0.16	-0.41	-0.42	-0.15	-0.43	0.26	-0.16	-0.49	-0.78	-0.45	-0.26	-0.44	-0.18	-0.35	-0.37	0.37	-0.38		1.0
Selling And Marketing Expenses	-0.13	-0.08	-0.19	-0.31	-0.31	-0.16	-0.41	-0.42	-0.15	-0.43	0.26	-0.16	-0.49	-0.78	-0.45	-0.26	-0.44	-0.18	-0.35	-0.37	0.37	-0.38	1.0

Click cells to compare fundamentals

CytomX Therapeutics Account Relationship Matchups

CytomX Therapeutics income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	2.6M	5.5M	2.7M	2.4M	2.2M	2.3M
Interest Expense	10.8M	1.8M	172K	2.0M	2.3M	2.1M
Selling General Administrative	36.8M	36.0M	39.2M	42.8M	30.0M	28.8M
Total Revenue	57.5M	100.4M	69.6M	53.2M	101.2M	54.2M
Gross Profit	57.5M	100.4M	69.6M	53.2M	101.2M	54.2M
Other Operating Expenses	168.4M	149.0M	153.4M	154.5M	107.7M	115.4M
Operating Income	(110.9M)	(48.6M)	(83.8M)	(101.3M)	(6.5M)	(6.8M)
Ebit	(110.9M)	(83.4M)	(83.8M)	(101.3M)	(6.5M)	(6.8M)
Research Development	131.6M	112.9M	114.2M	111.6M	77.7M	86.7M
Ebitda	(108.3M)	(78.0M)	(81.1M)	(98.9M)	(4.3M)	(4.5M)
Cost Of Revenue	105.5M	0.0	5.8M	5.9M	2.2M	2.1M
Total Operating Expenses	168.4M	149.0M	153.4M	154.5M	107.7M	115.4M
Income Before Tax	(102.7M)	(46.8M)	(83.6M)	(99.3M)	3.3M	3.5M
Total Other Income Expense Net	8.2M	1.8M	172K	2.0M	9.8M	10.3M
Net Income	(102.2M)	(32.9M)	(80.6M)	(97.3M)	(569K)	(597.5K)
Income Tax Expense	(427K)	(13.9M)	(3.0M)	(2.0M)	3.9M	4.1M
Net Income From Continuing Ops	(102.2M)	(32.9M)	(83.6M)	(115.9M)	(10.2M)	(10.7M)
Net Income Applicable To Common Shares	(102.2M)	(32.9M)	(83.6M)	(115.9M)	(104.3M)	(109.5M)
Tax Provision	14.3M	(427K)	(13.9M)	0.0	2.8M	3.0M
Interest Income	8.4M	1.8M	255K	1.7M	8.1M	4.1M
Net Interest Income	8.4M	1.8M	255K	1.7M	8.1M	4.3M
Non Operating Income Net Other	7.6M	8.2M	1.8M	172K	154.8K	147.1K
Reconciled Depreciation	2.6M	2.6M	2.7M	2.4M	2.3M	2.5M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ESRT	Empire State Realty
C	Citigroup
C	Citigroup

Additional Tools for CytomX Stock Analysis

When running CytomX Therapeutics' price analysis, check to measure CytomX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CytomX Therapeutics is operating at the current time. Most of CytomX Therapeutics' value examination focuses on studying past and present price action to predict the probability of CytomX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CytomX Therapeutics' price. Additionally, you may evaluate how the addition of CytomX Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

CytomX Historical Income Statement

About CytomX Income Statement Analysis

CytomX Therapeutics Income Statement Chart

Total Revenue

Gross Profit

Other Operating Expenses

CytomX Therapeutics income statement Correlations

CytomX Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

CytomX Therapeutics income statement Accounts

Also Currently Popular

Additional Tools for CytomX Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Gross Profit	+ 1.0	Total Revenue
Research Development	+ 1.0	Other Operating Expenses
Total Operating Expenses	+ 1.0	Other Operating Expenses
Ebitda	+ 1.0	Ebit
Total Operating Expenses	+ 1.0	Research Development
Selling And Marketing Expenses	+ 1.0	Extraordinary Items

Selling And Marketing Expenses	- 0.78	Total Other Income Expense Net
Extraordinary Items	- 0.78	Total Other Income Expense Net
Total Operating Expenses	- 0.78	Ebit
Research Development	- 0.78	Ebit
Ebit	- 0.78	Other Operating Expenses
Total Operating Expenses	- 0.77	Ebitda